1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag

Magle Chemoswed Holding Reports Financial Results For First Quarter 2022

MARKN.

Magle Chemoswed Holding today reported financial results for the first quarter ended March 31, 2022, with solid profit growth year on year.

Q3 2021 KEY INDICATORS

  • Net sales amounted to 30.2 MSEK (30.4).
  • EBITDA equaled 6.5 MSEK (3.5).
  • Operating profit (EBIT) is 3.4 MSEK (0.8)
  • Profit after tax amounted to 2.9 MSEK (1.0)
  • Earnings per share amounted to SEK 0,27 (0,09) per share

RECENT BUSINESS ACCOMPLISHMENTS

  • EmboCept® S is approved in the CIRSE European Guidelines
  • Commercial order for AXXO Woundgel received
  • ISO13485:2016 certification inspection passed
  • Magle Chemoswed funds new post-doc position at Copenhagen University

“We continue to execute on our strategy to be a leader in high-quality, life-changing healthcare innovations to meet medical needs through scientific excellence and establish a risk-to-growth balance acceptable to the business. I see strong momentum in our business areas with great promise for the future. In the quarter, we saw sales equal to the previous year same quarter. The gross margin at 91% (88%) indicates underlying stability while absorbing cost increases in the supply chain. Our EBITDA margin was 21% (12%), a very pleasing result for the start of the year”, said Justin Pierce, CEO of Magle Chemoswed Holding.

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

2022 Q1 Released

Datum 2022-05-05, kl 08:30
Källa MFN
Bifogade filer
2022 Q1 Released
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.